<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149815">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02091388</url>
  </required_header>
  <id_info>
    <org_study_id>LY03004 MD</org_study_id>
    <nct_id>NCT02091388</nct_id>
  </id_info>
  <brief_title>Bioavailability of LY03004 and Risperdal® Consta®</brief_title>
  <official_title>A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luye Pharma Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luye Pharma Group Ltd.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the bioavailability of LY03004  compared to Risperdal Consta as well
      as the evaluate the safety and tolerability and preliminary efficacy of LY03004 with repeat
      injections
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To assess the relative bioavailability of LY03004 compared to Risperdal® Consta® at 25
           mg following multiple intramuscular injections at steady-state;

        -  To evaluate the safety and tolerability of LY03004 following repeated intramuscular
           injections

        -  To evaluate the preliminary efficacy of LY03004 following repeated intramuscular
           injections
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cmax, Tmax, for Relative bioavailability of LY03004 compared to Risperdal® Consta®</measure>
    <time_frame>113 Days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>113 Days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of the PANSS score for the Preliminary efficacy of LY03004</measure>
    <time_frame>113 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>LY03004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 intramuscular injections 25 mg over 113 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperdal® Consta®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 intramuscular injections 25 mg over 113 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY03004</intervention_name>
    <arm_group_label>LY03004</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperdal® Consta®</intervention_name>
    <arm_group_label>Risperdal® Consta®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients aged 18 to 65 years old

          2. Patients must have a DSM-IV-TR diagnosis of schizophrenia or schizoaffective disorder
             based on the Mini-International Neuropsychiatric Interview (MINI)

          3. Patients must be clinically stable on antipsychotic medications other than
             risperidone or paliperidone or clozapine for at least 4 weeks prior to screening,
             based on clinical assessments AND a Positive and Negative Syndrome Scale (PANSS)
             total score less than or equal 70 at Screening Visit

          4. Patients with a Body Mass Index in range of 18.0 to 35.0

          5. Patients with an Informed Consent Form signed by the patient or legally authorized
             representative

        Exclusion Criteria:

          1. Patients with a mental disorders other than schizophrenia or schizoaffective
             disorder, according to the DSM-IV-TR

          2. Patients who received oral risperidone or paliperidone or clozapine within 14 days
             prior to screening, or Risperdal® Consta® within 100 days prior to screening or
             paliperidone palmitate within 10 months prior to screening

          3. Patients with neuroleptic malignant syndrome or physical fatigue associated with
             dehydration or malnutrition

          4. Patients who pose a significant risk of a suicide attempt based on history,
             investigator's judgment or have answered &quot;yes&quot; to the questions 4 or 5 for current or
             past 30 days on the screening form of the Columbia Suicide Severity Rating Scale
             (C-SSRS)

          5. Patients with a history of sensitivity to akathisia and other EPS, especially with
             previous use of risperidone or paliperidone

          6. Patients with uncontrolled diabetes mellitus as indicated by a HbA1c level greater
             than or equal to 7%

          7. Patients with a history of or currently having epilepsy or convulsion disorders

          8. Patients who have had electroconvulsive therapy within the past 2 months prior to
             screening

          9. Patients who used medication known to be an inducer or inhibitor for CYP 2D6 within 2
             weeks prior to screening

         10. Patients with a history of allergic reaction to risperidone or to the excipients of
             LY03004

         11. Patients who have met DSM-IV-TR criteria for substance abuse or dependence with the
             exception of caffeine or nicotine in the past 6 months prior to screening

         12. Patients with a history of clinically relevant cardiac arrhythmia's, cardiovascular
             disease, thyrotoxicosis, parkinsonism, or hemorrhagic diathesis

         13. Patients who are currently taking medications with primarily CNS activities such as
             antidepressants, mood stabilizers or anticonvulsants

         14. Patients who have participated in a clinical trial of another investigational drug
             within 30 days prior to screening

         15. Female patients who are pregnant or are breastfeeding or are of childbearing
             potential without adequate use of contraception

         16. Patients who have any clinically relevant hepatic, renal and cardiac dysfunction, or
             other medical condition or laboratory abnormality, which in the judgment of the
             investigator would interfere with the subject's ability to participate in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Li</last_name>
    <role>Study Chair</role>
    <affiliation>Luye Pharma Group Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simon Li</last_name>
    <email>simonli@luye.cn</email>
  </overall_contact>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 18, 2014</lastchanged_date>
  <firstreceived_date>March 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
